XML 177 R157.htm IDEA: XBRL DOCUMENT v3.25.0.1
Events occurring after the reporting period, Acquisition of Assets (Details) - Subsequent Event [Member]
$ in Millions
Jan. 30, 2025
USD ($)
Product
Maximum [Member] | Dr. Christian Behrenbruch [Member]  
Consideration [Abstract]  
Percentage of ownership interest 1.00%
Next-Generation Therapeutic Assets [Member]  
Consideration [Abstract]  
Final purchase price $ 45
Cash payable 10
Equity issued $ 31
Indemnity period 15 months
Contingent consideration $ 185
Next-Generation Therapeutic Assets [Member] | Minimum [Member]  
Consideration [Abstract]  
Number of products to be developed for royalties and sublicense fees payment | Product 4
Next-Generation Therapeutic Assets [Member] | Maximum [Member]  
Consideration [Abstract]  
Deferred payment $ 4